Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 666-674

  Schiavon, L L ^a,b   Narciso Schiavon, J L ^a   Carvalho Filho, R J ^a   Sampaio, J P ^a   Medina Pestana, J O ^a   Lanzoni, V P ^a   Silva, A E B ^a   Ferraz, M L G ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

End stage renal disease; Haemodialysis; Hepatitis C; Hyaluronic acid; YKL 40

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HYALURONIC ACID;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLYCOPROTEINS; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA;

EID: 49649094025     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00992.x     Document Type: Article

References (47)

1. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993 44 : 1322 1326.
2. Huang CS, Ho MS, Yang CS, Lee CL, Tan CA. Hepatitis C markers in hemodialysis patients. J Clin Microbiol 1993 31 : 1764 1769.
3. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004 20 : 1271 1277.
4. Legendre C, Garrigue V, Le Bihan C et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998 65 : 667 670.
5. Gentil MA, Rocha JL, Rodriguez-Algarra G et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999 14 : 2455 2460.
6. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004 78 : 745 750.
7. Manga Sahin G, Sahin S, Kantarci G, Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplant Proc 2006 38 : 499 501.
8. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003 18 : 1071 1081.
9. Rocha CM, Perez RM, Ferreira AP et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006 26 : 305 310.
10. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001 344 : 495 500.
11. Sabovic M, Salobir B, Preloznik Zupan I, Bratina P, Bojec V, Buturovic Ponikvar J. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2005 34 : 274 278.
12. Ozdogan M, Ozgur O, Boyacioglu S et al. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 1996 74 : 442 443.
13. Terjung B, Lemnitzer I, Dumoulin FL et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003 67 : 138 145.
14. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97 : 2614 2618.
15. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003 38 : 427 432.
16. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 1457.
17. Scheuer PJ. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003 38 : 1356 1358.
18. Schiavon LL, Schiavon JL, Filho RJ et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007 46 : 307 314.
19. Montazeri G, Estakhri A, Mohamadnejad M et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005 5 : 32.
20. Trocme C, Leroy V, Sturm N et al. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006 13 : 643 651.
21. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998 5 : 187 192.
22. Johansen JS, Christoffersen P, Moller S et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000 32 : 911 920.
23. Zheng M, Cai WM, Weng HL, Liu RH. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002 8 : 1073 1076.
24. Laurent TC, Laurent UB, Fraser JR. Serum hyaluronan as a disease marker. Ann Med 1996 28 : 241 253.
25. Fraser JR, Laurent TC, Pertoft H, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981 200 : 415 424.
26. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006 53 : 172 209.
27. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996 35 : 553 559.
28. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 526.
29. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 : 839 843.
30. Nunes D, Fleming C, Offner G et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005 40 : 538 544.
31. Zheng M, Cai WM, Zhao JK, Zhu SM, Liu RH. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value. Acta Trop 2005 96 : 148 152.
32. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003 39 : 179 186.
33. Saitou Y, Shiraki K, Yamanaka Y et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005 11 : 476 481.
34. Esmat G, Metwally M, Zalata KR et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007 46 : 620 627.
35. Johansen JS, Moller S, Price PA et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997 32 : 582 590.
36. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006 26 : 864 871.
37. Stickel F, Poeschl G, Schuppan D et al. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol 2003 15 : 945 950.
38. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004 127 : 1704 1713.
39. Furusyo N, Hayashi J, Kanamoto-Tanaka Y et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Dig Dis Sci 2000 45 : 2221 2228.
40. Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004 41 : 935 942.
41. Halfon P, Bourliere M, Penaranda G et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005 4 : 1 7.
42. Parise ER, Oliveira AC, Figueiredo-Mendes C et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006 26 : 1095 1099.
43. Stenvinkel P, Heimburger O, Wang T, Lindholm B, Bergstrom J, Elinder CG. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 1999 34 : 1083 1088.
44. Woodrow G, Turney JH, Davison AM, Cooper EH. Serum hyaluronan concentrations predict survival in patients with chronic renal failure on maintenance haemodialysis. Nephrol Dial Transplant 1996 11 : 98 100.
45. Ozasa H, Chichibu K, Tanaka Y, Kondo T, Kitajima K, Ota K. Relationship between plasma levels of hyaluronic acid and amyloid-associated osteoarthropathy in chronic hemodialysis patients. Nephron 1992 61 : 187 191.
46. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003 42 : 864 881.
47. Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999 19 : 183 187.